PolyPid Earnings Call Transcripts
Fiscal Year 2026
-
D-PLEX₁₀₀ is nearing NDA submission, with robust Phase 3 data showing significant reductions in surgical site infections and related complications. Regulatory alignment and market preparation are strong, with plans for label expansion and a focus on strategic partnerships.
-
A novel drug delivery platform is advancing toward FDA approval, with D-PLEX 100 showing strong phase 3 results in reducing surgical site infections. Commercialization plans include a U.S. partnership, and financial resources are sufficient through 2026.
Fiscal Year 2025
-
SHIELD II Phase III trial success and positive FDA feedback position D-PLEX100 for a rolling NDA submission in Q1 2026, with advanced U.S. partnership talks and a strengthened balance sheet. The company is transitioning to commercialization, introducing the Kynatrix platform, and expects cash to last into H2 2026.
-
D-PLEX100, a novel local antibiotic delivery system, demonstrated a 60% reduction in surgical site infections and strong safety in a large phase 3 trial. Regulatory submission is planned for early 2026, with high anticipated adoption among surgeons and hospitals due to robust efficacy, safety, and economic benefits.
-
Q3 2025 saw regulatory, commercial, and manufacturing progress for D-PLEX100, with a pre-NDA FDA meeting set for December and NDA submission on track for early 2026. Financial discipline was maintained, net loss improved, and market access studies confirmed strong U.S. demand.
-
D-PLEX100 demonstrated strong Phase 3 results in reducing surgical site infections, with NDA submission planned for Q1 next year. The product targets a large market, offers significant hospital cost savings, and has attracted strong commercial interest. Cash runway extends into 2026.
-
Q2 2025 saw pivotal phase III results for D-PLEX 100, showing strong efficacy and safety in reducing surgical site infections, driving regulatory and commercial momentum. Financials improved with a strengthened cash position and ongoing partnership discussions in the U.S. and Europe.
-
SHIELD II phase III results showed D-PLEX100 plus standard of care significantly reduced surgical site infections and related complications in abdominal colorectal surgery, with robust efficacy and safety. Regulatory submissions are planned for 2026, and strong partnership and commercial preparations are underway.
-
D‑PLEX₁₀₀ is nearing a pivotal phase III milestone, with top-line data expected by end of Q2 2025. The product targets a large surgical infection market, with strong prior efficacy, robust IP, and commercial partnerships in place. Funding is secured through key inflection points.
-
Enrollment for the pivotal Shield 2 phase 3 trial of D-PLEX 100 is complete, with top-line data expected soon. Cash runway extends into Q3 2025, with potential for further funding, and NDA submission is targeted for early 2026.
-
The company presented its PLEX drug delivery platform and lead product D-PLEX 100, which is nearing completion of a pivotal Phase 3 trial for SSI prevention. Strong efficacy signals, robust market exclusivity, and a clear commercialization strategy position the product for near-term milestones and potential partnerships.
Fiscal Year 2024
-
Shield II phase III trial for D-PLEX100 is nearing completion, with top-line results expected in Q2 2025 and a potential NDA submission to follow. Financially, a $14.5M private placement extends the cash runway into Q3 2025, and partnering discussions are advancing for U.S. commercialization.
-
A proprietary drug delivery platform enables prolonged antibiotic release for surgical infection prevention, with phase III data expected in Q1 2025. Strong efficacy in high-risk patients, robust financial planning, and strategic partnerships position the company for major commercial milestones.
-
SHIELD II trial enrollment accelerated, with top-line results expected next quarter and strong global market interest. Cash runway extends into 2025, with potential for 2026 if warrants are exercised. D-PLEX 100 addresses a rising unmet need as post-COVID infection rates increase.
-
SHIELD II trial for D-PLEX100 is progressing well, with robust enrollment and no safety issues, and interim analysis expected in Q4 2024. Financial position strengthened by recent PIPE financing, extending cash runway into 2025. Commercialization and partnership discussions are ongoing.